Experimental drug KER-065 aims to slow muscle decline in duchenne muscular dystrophy
NCT ID NCT07704099
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This phase 2 trial tests an experimental drug called KER-065 in adult and pediatric males with Duchenne Muscular Dystrophy (DMD), a genetic condition that causes progressive muscle weakness. The study includes both those who can walk and those who cannot, and all participants must be on a stable steroid regimen. The main goal is to check the drug's safety and how well it works, with researchers also measuring how the body processes KER-065 and whether it triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental drug called KER-065
- What this could lead to
- If successful, KER-065 could offer a new treatment option to slow muscle decline and improve function in people with Duchenne Muscular Dystrophy.
- What could go wrong
- This is an early-phase trial with only 36 participants, so results may not apply to all patients. The drug may cause side effects or fail to show meaningful benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a massive patient database unlock new treatments for muscular dystrophy?
- Umbilical cord stem cells aim to slow muscle loss in duchenne boys
- Experimental drug aims to preserve arm and lung function in boys with advanced duchenne
- Can early parent coaching help infants with rare genetic disorders thrive?
- Newborn screening study aims to catch rare diseases at birth
- One-Time gene infusion aims to fight duchenne muscular dystrophy